Aura Biosciences to Participate in Upcoming Investor Conferences
05/25/2022 - 07:00 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences:
Cowen’s Virtual 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022 . Fireside chat at 9:00 a.m. ET .
Jefferies Global Healthcare Conference at the New York Marriot Marquis on Wednesday, June 8, 2022 . Presentation at 1:30 p.m. ET .
A live webcast of the Cowen fireside chat and Jefferies presentation will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations , where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is currently in development for ocular cancers, with an ongoing Phase 2 dose escalation clinical trial evaluating first-line treatment of choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, leveraging Aura’s technology platform, Aura is developing AU-011 more broadly across multiple cancers, starting with a planned Phase 1 clinical trial in patients with non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA.
For more information, visit aurabiosciences.com , or follow us on Twitter and LinkedIn.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220525005111/en/
Investor and Media Contact:
Matthew DeYoung
Argot Partners
212-600-1902 | aura@argotpartners.com
Source: Aura Biosciences Inc.
AURA Rankings
#4398 Ranked by Stock Gains
AURA Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About AURA
at aura biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. by safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. our lead program in ocular melanoma (om), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. the goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. by enabling physicians to treat cancer mo